Le Lézard
Classified in: Health, Science and technology

TGF-beta/Receptor Inhibitors Competitor Analysis 2019 - ResearchAndMarkets.com


The "Competitor Analysis: TGF-beta/Receptor Inhibitors" report has been added to ResearchAndMarkets.com's offering.

This Competitive Intelligence report about TGF-beta/Receptor Inhibitors evaluates the landscape of investigational new molecular entities targeting transforming growth factor-beta (TGF-) and TGF- receptor kinase for the treatment of cancer or fibrosis as of September 2019.

Several cytokines and growth factors are involved in the tight regulation of either antitumor immunity or immunosuppressive tumor-promoting inflammation within the tumor microenvironment (TME), of which transforming growth factor-beta (TGF-) is of particular importance. In mammals, three TGF- isoforms are described (TGF-1, 2, and 3) which are the primary mediators of TGF- cell transduction. All isoforms are synthesised as propeptides that form dimers which require maturation before being able to bind to their receptors. These dimers are composed of the C-terminal TGF- ligand as well as an N-terminal latency-associated propeptide (LAP), with which the complex gets sequester to proteins of the extracellular matrix (ECM).

As preclinical studies implicate the use of TGF- inhibition as a potential therapeutic target, monoclonal antibodies against all three isoforms of TGF-, as well as TGF-R inhibitors, are currently tested in various solid cancers. As the response to anti-PD-1 monotherapy appears to be mainly limited by the number of preexisting cytotoxic T cells, concurrent TGF- inhibition provides a powerful strategy to (a) improve T cell priming within the lymph nodes, (b) enhance cytotoxic destruction of tumor cells, and (c) reduce the appearance of immune-suppressive immune cells.

The report includes a compilation of currently active projects in research and development of TGF-/R inhibitors for the treatment of fibrosis and cancer, respectively. In addition, the report lists company-specific R&D pipelines of TGF- and TGF- receptor kinase inhibitors. Competitor projects are listed in a tabular format providing information on:

Key Topics Covered:

1) Cancer Indications

2) Non-Cancer Indications with TGF- Inhibition

3) Corporate RORgamma Antagonist & Agonist R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/r/o5nefm


These press releases may also interest you

at 15:00
Immunostics Inc. (Boditech USA) and Dr. Scott Benson, an associate professor at the University of Utah Medical School, announce a COVID-19 testing solution and protocol for universities and colleges. With nearly all universities and colleges...

at 15:00
The "Technology Landscape, Trends and Opportunities in the Global 3D Printing Medical Device Market" report has been added to ResearchAndMarkets.com's offering. This report analyzes technology maturity, degree of disruption, competitive intensity,...

at 15:00
ADCO Hearing Products is manufacturing and selling face masks that address the issues that those who are hard of hearing experience wearing common masks, such as being unable to read lips and facial expressions, as well as uncomfortable ear straps....

at 15:00
Chief Executive Officer of MassageLuXe, a fast-growing luxury spa franchise, Mark Otter, recently was published by the Forbes Business Council. This is his first article to be featured by Forbes. The article, How Your Personal Services Business Can...

at 14:59
The Medical Board of California's decision to allow Dr. Arthur Park to continue practicing, despite a 20-year track record of negligence causing catastrophic injuries and death in the Bakersfield community, will unconscionably place even more...

at 14:50
The alprazolam market is poised to grow by USD 90.33 million during 2020-2024, progressing at a CAGR of over 4% during the forecast period. Request free sample pages Read the 159-page report with TOC on "Alprazolam Market Analysis Report by Type...



News published on 21 october 2019 at 10:30 and distributed by: